Candel Therapeutics, Inc. CADL EPS (Diluted)
EPS (Diluted) at other companies
Other financials
Where this comes from
Reported directly by Candel Therapeutics, Inc. in its filing.
Tagged under the XBRL concept us-gaap:EarningsPerShareDiluted.
The official record: Candel Therapeutics, Inc.’s 10-Q, filed May 14, 2026, on SEC EDGAR. View the filing →
Ask your AI about Candel Therapeutics, Inc.'s eps (diluted).
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Candel Therapeutics, Inc.'s EPS (diluted)?
- Candel Therapeutics, Inc. (CADL) reported EPS (diluted) of -$0.14 in Q1 2026.
- How has Candel Therapeutics, Inc.'s EPS (diluted) changed year-over-year?
- Candel Therapeutics, Inc.'s EPS (diluted) decreased by 207.7% year-over-year, from $0.13 to -$0.14.
- What is the long-term trend for Candel Therapeutics, Inc.'s EPS (diluted)?
- Over 3 years (2022 to 2025), Candel Therapeutics, Inc.'s EPS (diluted) has grown at a 4.0% compound annual growth rate (CAGR), from -$0.64 to -$0.72.
- What does EPS (diluted) mean?
- Net income divided by the weighted-average number of shares outstanding plus all potentially dilutive securities (stock options, convertibles, warrants). The most conservative EPS measure.